Opaleye Management Inc. purchased $8K of GRCE (indirect holdings)
Opaleye Management Inc. purchased 4,256 indirectly-held shares of Grace Therapeutics, Inc. (GRCE) at $1.88 on 2026-10-19.
How this was made
The 30-second read
Why it matters
The $8K purchase is unlikely to move the stock price materially, but it adds a data point for monitoring insider sentiment.
Market read
Routine insider transaction with minimal market impact; useful for tracking insider activity.
What to watch
Potential future insider activity or upcoming clinical milestones for Grace Therapeutics.
Background
Grace Therapeutics (GRCE) is a biotech company listed on NASDAQ. The filing is a standard Form 4 disclosure of an insider purchase.
Ticker impact
SEC Form 4 shows Opaleye Management Inc. purchased 4,256 shares of Grace Therapeutics at $1.88, a $8K insider buy.
negligible upward pressure as the market may view the buy as a modest vote of confidence
The transaction size ($8K) is trivial relative to market cap; no material change in ownership.
Market effects
None; the purchase does not signal broader sector trends.
None; limited to a micro‑cap biotech with no regional ripple.
None; the filing is a routine insider transaction.
Counterpoint
Even a small insider buy could hint at upcoming positive news not yet public.
Key entities
- CompanyGrace Therapeutics, Inc.
Issuer of the securities purchased.
- InsiderOpaleye Management Inc.
Purchaser and 10% owner of Grace Therapeutics.
